Therapy Areas: Infectious Diseases
Adagio Therapeutics Names COVID-19 Vaccine Expert Hering as Chief Operating Officer
19 July 2021 - - David Hering has been appointed as US-based biotechnology company Adagio Therapeutics, Inc's chief operating officer, the company said.

Hering joins Adagio from Pfizer (NYSE: PFE), where he most recently served as the global mRNA business lead, a business specifically created to optimize management of COVID-19 efforts, and led the launch of the first-ever COVID-19 vaccines worldwide.

David Hering is a life sciences leader who brings more than 25 years of experience creating and growing value for companies within the pharmaceutical and life sciences industry.

Hering has spent much of his career leading functions within vaccine franchises at some of the top pharmaceutical companies.

Prior to his most recent role at Pfizer, Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products in COVID-19 and meningococcal and pneumococcal diseases.

Before Pfizer, he held a number of roles of increasing responsibility at Novartis Vaccines, most recently as head of North America where he led an organization responsible for a portfolio of four vaccine products in meningitis and travel.

Earlier, he was a consultant for Keystone Strategy, advising clients within the biotech industry, and held manufacturing-focused roles at Merck and Co., Inc. Hering holds an MBA from Harvard Business School and B.S. in operations research and industrial engineering from Cornell University.

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential.

The company's portfolio of antibodies has been optimized using Adimab's antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability.

Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20.

Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.


Related Headlines